Clinical Trials Directory

Trials / Completed

CompletedNCT03724812

FlexNav EU CE Mark Study

Assessment of the Abbott FlexNav™ Delivery System for Portico Transcatheter Aortic Valve Implantation in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
46 (actual)
Sponsor
Abbott Medical Devices · Industry
Sex
All
Age
21 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The purpose of this clinical investigation is to characterize the safety of the next-generation FlexNav™ Delivery System for transfemoral implantation of the Portico™ Transcatheter Aortic Heart Valve in symptomatic severe aortic stenosis patients who are considered of high or extreme risk for surgical aortic valve replacement. Data from the study will be used to support CE Mark of the FlexNav™ Delivery System and Loading System in Europe.

Detailed description

The FlexNav European Union (EU) study will be conducted as a prospective, multi-center, single-arm investigational study. High or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico™ Transcatheter Aortic Heart Valve implantation via a transfemoral access approach will undergo a Portico valve implant using the next-generation FlexNav Delivery System. Subject data will be collected at screening, baseline, pre-procedure, peri-procedure, post-procedure, discharge, 30 days, 6 months and 1-year from the index procedure.

Conditions

Interventions

TypeNameDescription
DEVICEPortico Valve and FlexNav™ Delivery SystemSubjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach

Timeline

Start date
2019-02-26
Primary completion
2020-01-14
Completion
2021-02-10
First posted
2018-10-30
Last updated
2021-11-24
Results posted
2021-03-16

Locations

6 sites across 4 countries: Denmark, Italy, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT03724812. Inclusion in this directory is not an endorsement.

FlexNav EU CE Mark Study (NCT03724812) · Clinical Trials Directory